311 related articles for article (PubMed ID: 26465170)
1. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.
Yamamoto T; Nair P; Largent-Milnes TM; Jacobsen NE; Davis P; Ma SW; Yamamura HI; Vanderah TW; Porreca F; Lai J; Hruby VJ
J Med Chem; 2011 Apr; 54(7):2029-38. PubMed ID: 21366266
[TBL] [Abstract][Full Text] [Related]
3. Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.
Nair P; Yamamoto T; Largent-Milnes TM; Cowell S; Kulkarni V; Moye S; Navratilova E; Davis P; Ma SW; Vanderah TW; Lai J; Porreca F; Hruby VJ
Bioorg Med Chem Lett; 2013 Sep; 23(17):4975-8. PubMed ID: 23899615
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.
Yamamoto T; Nair P; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Vanderah TW; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 2007 Jun; 50(12):2779-86. PubMed ID: 17516639
[TBL] [Abstract][Full Text] [Related]
5. Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities.
Nair P; Yamamoto T; Cowell S; Kulkarni V; Moye S; Navratilova E; Davis P; Ma SW; Vanderah TW; Lai J; Porreca F; Hruby VJ
Bioorg Med Chem Lett; 2015 Sep; 25(17):3716-20. PubMed ID: 26212775
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the Anti-Nociceptive Potential of NK2 and NK3 Ligands in the Design of New Multifunctional μ/δ-Opioid Agonist-Neurokinin Antagonist Peptidomimetics.
Gadais C; Piekielna-Ciesielska J; De Neve J; Martin C; Janecka A; Ballet S
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500841
[TBL] [Abstract][Full Text] [Related]
7. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
[TBL] [Abstract][Full Text] [Related]
8. Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.
Ballet S; Feytens D; Buysse K; Chung NN; Lemieux C; Tumati S; Keresztes A; Van Duppen J; Lai J; Varga E; Porreca F; Schiller PW; Vanden Broeck J; Tourwé D
J Med Chem; 2011 Apr; 54(7):2467-76. PubMed ID: 21413804
[TBL] [Abstract][Full Text] [Related]
9. The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Yamamoto T; Nair P; Jacobsen NE; Davis P; Ma SW; Navratilova E; Moye S; Lai J; Yamamura HI; Vanderah TW; Porreca F; Hruby VJ
J Med Chem; 2008 Oct; 51(20):6334-47. PubMed ID: 18821747
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors.
Wtorek K; Adamska-Bartłomiejczyk A; Piekielna-Ciesielska J; Ferrari F; Ruzza C; Kluczyk A; Piasecka-Zelga J; Calo' G; Janecka A
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817441
[TBL] [Abstract][Full Text] [Related]
11. Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists.
Yamamoto T; Nair P; Jacobsen NE; Vagner J; Kulkarni V; Davis P; Ma SW; Navratilova E; Yamamura HI; Vanderah TW; Porreca F; Lai J; Hruby VJ
J Med Chem; 2009 Aug; 52(16):5164-75. PubMed ID: 20560643
[TBL] [Abstract][Full Text] [Related]
12. A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Yamamoto T; Nair P; Vagner J; Largent-Milnes T; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Yamamura HI; Vanderah TW; Porreca F; Hruby VJ
J Med Chem; 2008 Mar; 51(5):1369-76. PubMed ID: 18266313
[TBL] [Abstract][Full Text] [Related]
13. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW
Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
15. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
16. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist - neurokinin-1 antagonist peptidomimetics.
Guillemyn K; Kleczkowska P; Lesniak A; Dyniewicz J; Van der Poorten O; Van den Eynde I; Keresztes A; Varga E; Lai J; Porreca F; Chung NN; Lemieux C; Mika J; Rojewska E; Makuch W; Van Duppen J; Przewlocka B; Vanden Broeck J; Lipkowski AW; Schiller PW; Tourwé D; Ballet S
Eur J Med Chem; 2015 Mar; 92():64-77. PubMed ID: 25544687
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
[TBL] [Abstract][Full Text] [Related]
19. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
[TBL] [Abstract][Full Text] [Related]
20. The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety.
Yamamoto T; Nair P; Ma SW; Davis P; Yamamura HI; Vanderah TW; Porreca F; Lai J; Hruby VJ
Bioorg Med Chem; 2009 Oct; 17(20):7337-43. PubMed ID: 19762245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
